Aβ42 Aptamer-Gold Nanoparticle Eye Drops for Alzheimer's Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for early screening of Alzheimer's disease are complex, require expensive instruments, and lack convenience, as they involve preparing magnetic beads or using phototransistor devices that necessitate professional operation.
Innovation Solution
Development of color-changing eye drops containing Aβ42 aptamer-gold nanoparticles that change color when mixed with a tear sample, allowing for the analysis of the Aβ40:Aβ42 ratio without the need for expensive instruments, using a pharmaceutically acceptable carrier and electrochemical impedance spectroscopy for detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If phototransistor device is used for detecting beta-amyloid, then detection capability is improved, but device complexity and ease of operation deteriorate due to requiring professional equipment and skilled operation
Solution Approach 1:
The patent uses gold nanoparticles that exhibit color changes based on their aggregation state. When Aβ42 binds to the aptamer-gold nanoparticle conjugate, it causes nanoparticle aggregation that shifts the color from red to purple/blue. This colorimetric change provides a simple, instrument-free detection method that maintains measurement precision while eliminating device complexity.
Solution Approach 2:
The patent replaces the phototransistor-based electrical detection system with a colorimetric chemical detection system. Instead of using electronic devices to measure photocurrent differences, the invention uses visual color changes of gold nanoparticles that can be observed directly or with simple colorimetric analysis, substituting complex mechanical/electrical systems with simpler chemical indicators.
2Measurement precision
If magnetic beads are used for labeling cells with beta-amyloid biomarker, then detection accuracy is improved, but ease of manufacture deteriorates due to complicated preparation process
Solution Approach 1:
The patent creates a composite material consisting of gold nanoparticles conjugated with Aβ42-specific aptamers. This composite structure combines the high surface area and optical properties of gold nanoparticles with the specific binding capability of aptamers, achieving detection accuracy comparable to magnetic bead methods while simplifying the preparation process through a single conjugate formulation.
Solution Approach 2:
The patent employs a pre-formulated aptamer-gold nanoparticle conjugate that can be stored and used directly without complex preparation. This disposable-like approach eliminates the need for complicated in-lab preparation of magnetic beads and antibody conjugates, allowing users to simply mix the conjugate with tear samples and observe color changes, significantly improving ease of manufacture and user operation.
3Measurement precision
If optical instruments are used for non-invasive beta-amyloid detection, then measurement precision is improved, but ease of operation and cost deteriorate due to expensive equipment and professional operation requirements
Solution Approach 1:
The patent uses the intrinsic color-changing property of gold nanoparticles upon aggregation. The color shift from red to purple/blue is visually observable and can be quantified using simple colorimetric methods or even visual inspection, eliminating the need for expensive optical instruments while maintaining sufficient detection precision for screening applications.
Solution Approach 2:
The aptamer-gold nanoparticle conjugate performs self-detection through its color-changing response when binding Aβ42 in tear samples. The system is self-indicating, requiring no external instrumentation or complex analysis equipment - the presence and concentration of Aβ42 are directly reflected in the color intensity and hue of the solution, enabling users to perform detection themselves without professional training.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid and early detection of Alzheimer's disease symptoms through a simple, cost-effective, and user-friendly method by observing color changes in the eye drops, eliminating the need for professional equipment and complex preparation processes.
Implementation Method 1
color-changing eye drops containing Aβ42 aptamer-gold nanoparticles that change color when mixed with a tear sample
Implementation Method 2
Aβ42 aptamer-gold nanoparticles (AuNPs)... analyzing a color change of the color-changing eye drop
Data Source
AI summary
The invention relates to color-changing eye drops for early screening Alzheimer's disease and an application thereof. The color-changing eye drop for early screening Alzheimer's disease comprises 1 pg/ml to 10 ng/ml of Aβ42 aptamer-gold nanoparticles (AuNPs) and a pharmaceutically acceptable carrier or vehicle thereof, which can be used to mix with a tear sample of a test subject to analyze a color change of the color-changing eye drop for determining the concentration proportion of Aβ40:Aβ42 contained in the tear sample of the test subject.